List of drugs that cannot be taken simultaneously with decavatinib

Deucravacitinib is an oral selective JAK1 inhibitor mainly used to treat moderate to severe plaque psoriasis and other immune-related diseases. Although this drug is convenient for oral use, there are potential drug interactions in clinical application, so strict attention needs to be paid to its combined use with certain drugs to ensure efficacy and safety.

First, deuterated colexitinib cannot be used concurrently with strong CYP1A2 or CYP2D6 inhibitors. Since decavatinib is mainly metabolized by CYP1A2 and CYP2D6, strong inhibitors may lead to a significant increase in blood concentration and increase the risk of adverse reactions, such as hematological abnormalities, infection risk, or liver function damage. Therefore, patients taking these inhibitors need to adjust their medication or choose an alternative drug.

Secondly, combined use with strong CYP1A2 or CYP2D6 inducers should be avoided. Inducers will accelerate the metabolism of decavatinib and reduce the plasma concentration, which may lead to reduced efficacy or poor disease control. For example, some anti-epileptic drugs and rifampicin antibiotics are strong inducers. Patients need to be cautious or adjust the dose when using decavatinib, and monitor the efficacy under the guidance of a doctor.

In addition, coadministration of deuterated colexitinib with immunosuppressants or other JAK inhibitors should be avoided. Combined use may lead to excessive immunosuppression and increase the risk of serious infections, thrombosis, and tumors. At the same time, attention should be paid to concomitant use with drugs that prolong the QT interval to avoid increasing the risk of arrhythmia. Clinically, doctors will develop an individualized plan based on the patient's medication history and potential interactions to ensure the safe and efficient use of deuterated colexitinib.

Reference materials:https://www.drugs.com/

xa0